BR112022021951A2 - Leriglitazona para o tratamento de inflamação pulmonar e doença pulmonar intersticial - Google Patents

Leriglitazona para o tratamento de inflamação pulmonar e doença pulmonar intersticial

Info

Publication number
BR112022021951A2
BR112022021951A2 BR112022021951A BR112022021951A BR112022021951A2 BR 112022021951 A2 BR112022021951 A2 BR 112022021951A2 BR 112022021951 A BR112022021951 A BR 112022021951A BR 112022021951 A BR112022021951 A BR 112022021951A BR 112022021951 A2 BR112022021951 A2 BR 112022021951A2
Authority
BR
Brazil
Prior art keywords
lung
leriglitazone
treatment
inflammation
interstitial
Prior art date
Application number
BR112022021951A
Other languages
English (en)
Portuguese (pt)
Inventor
Martinell Pedemonte Marc
Pilar Pizcueta Lalanza Maria
Vilalta Saura Anna
Traver López Estefania
Maria Poli Sonia
Izquierdo Useros Nuria
Original Assignee
Minoryx Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L filed Critical Minoryx Therapeutics S L
Publication of BR112022021951A2 publication Critical patent/BR112022021951A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112022021951A 2020-04-30 2021-04-30 Leriglitazona para o tratamento de inflamação pulmonar e doença pulmonar intersticial BR112022021951A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382356 2020-04-30
PCT/IB2021/053651 WO2021220250A1 (en) 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease

Publications (1)

Publication Number Publication Date
BR112022021951A2 true BR112022021951A2 (pt) 2022-12-13

Family

ID=70779625

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021951A BR112022021951A2 (pt) 2020-04-30 2021-04-30 Leriglitazona para o tratamento de inflamação pulmonar e doença pulmonar intersticial

Country Status (11)

Country Link
US (1) US20230172921A1 (cg-RX-API-DMAC7.html)
EP (1) EP4142720A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023525981A (cg-RX-API-DMAC7.html)
KR (1) KR20230035522A (cg-RX-API-DMAC7.html)
CN (1) CN116390725A (cg-RX-API-DMAC7.html)
AU (1) AU2021265345A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021951A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180351A1 (cg-RX-API-DMAC7.html)
IL (1) IL297771A (cg-RX-API-DMAC7.html)
MX (1) MX2022013021A (cg-RX-API-DMAC7.html)
WO (1) WO2021220250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
JP2026500743A (ja) * 2022-12-28 2026-01-08 ミノリックス セラピューティクス エセ.エレ. レリグリタゾンの最適投薬
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222272B1 (en) * 2008-08-07 2012-11-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US20120190637A1 (en) * 2009-10-14 2012-07-26 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
WO2011073662A1 (en) * 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
NZ725492A (en) 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
MX379710B (es) * 2016-12-01 2025-03-11 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.
MX2020013182A (es) * 2018-06-06 2021-02-26 Minoryx Therapeutics S L Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.

Also Published As

Publication number Publication date
EP4142720A1 (en) 2023-03-08
CN116390725A (zh) 2023-07-04
US20230172921A1 (en) 2023-06-08
MX2022013021A (es) 2023-01-16
IL297771A (en) 2022-12-01
CA3180351A1 (en) 2021-11-04
AU2021265345A1 (en) 2022-12-08
JP2023525981A (ja) 2023-06-20
KR20230035522A (ko) 2023-03-14
WO2021220250A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
MX2022013021A (es) Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial.
US20080194575A1 (en) Treatment for non-alcoholic-steatohepatitis
Muñoz-Espín et al. Cellular senescence: from physiology to pathology
RU2011133833A (ru) Способы лечения синдрома сосудистой утечки
CL2020003162A1 (es) Método de administración de una cantidad terapéuticamente efectiva de 5-[[4-[2-[5-(1- hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona
EP4545142A3 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
CA2687957C (en) Pharmaceutical containing ppar.delta. agonist
US10189826B2 (en) Heterocyclic compounds and methods of use
IL279186A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts
CN106999475B (zh) 异噁唑啉化合物用于治疗蠕形螨病的用途
CY1124116T1 (el) 5-[[4-[2-[5-(1-υδροξυαιθυλ)πυριδιν-2-υλ]αιθοξυ]φαινυλ]μεθυλ]-1,3-θειαζολιδινο-2,4-διονη για την θεραπεια της μη αλκοολικης λιπωδους νοσου του ηπατος
CA2786777A1 (en) Obesity small molecules
RU2013120064A (ru) Композиции и способы лечения глазного отека, неоваскуляризации и связанных с ними заболеваний
JP2014528450A5 (cg-RX-API-DMAC7.html)
SI3038622T1 (en) Heterocyclic compounds and methods of use
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
BR112021022843A2 (pt) Composto para tratamento de gota ou hiperuricemia
LT3559010T (lt) 5-[[4-[2-[5-(1-hidroksietil)-2-piridinil]etoksi]fenil]metil]-2,4-tiazolidindiono ir jo druskų gavimo būdas
DE60117584D1 (de) Verwendung von einem ppar delta aktivator zur behandlung von entzündlichen zuständen
RU2015126293A (ru) Производные тиазола в качестве ингибиторов тирозинкиназы брутона
Reynolds et al. Prospects for treatment of Porphyromonas gingivalis-mediated disease–immune-based therapy
JP2022540921A5 (cg-RX-API-DMAC7.html)
Kim et al. Effects of a Tumor Necrosis Factor‐α Antagonist on Experimentally Induced Rhinosinusitis
US20080207711A1 (en) Method for treating an ID2-related disorder
HK40050840A (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2878 DE 03-03-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.